The Concept of CMR
Slides, videos and moreEvaluating CMR
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
NCEP-ATP III
- 1Key Points (1 page)
- 2The NCEP-ATP III Statement of 2001 (2 pages)
- 3Etiology and Treatment of the Metabolic Syndrome and its Components According to NCEP-ATP III (4 pages)
- 4NCEP-ATP III Clinical Tools for Diagnosing the Metabolic Syndrome and Type 2 Diabetes/CVD Risk (3 pages)
- 5References (1 page)
Key Points
Page:
1 of 11
1 of 11
- NCEP-ATP III guidelines have emphasized that the metabolic syndrome is a secondary target of therapy beyond elevated LDL cholesterol.
- NCEP-ATP III guidelines have also singled out excess abdominal adipose tissue as a key feature of the metabolic syndrome.
- Other elements of the metabolic syndrome include atherogenic dyslipidemia, insulin resistance, a pro-inflammatory and pro-thrombotic profile, and high blood pressure.
- To date, numerous prospective studies have shown that the metabolic syndrome predicts CVD risk, with very few exceptions.
- Overall CVD risk related to the metabolic syndrome has been evaluated in meta-analyses, which have concluded that the metabolic syndrome increases relative risk of CVD.
- The metabolic syndrome is a stronger predictor of type 2 diabetes than CVD risk.
Page:
1 of 11
1 of 11
